Y. Wang

Retracted: Influence of genetic variants of IDH1, IDH2, TET2 and DNMT3A on cytarabine cytotoxicity in different populations.

J. Lamba, Y. Wang, 2017, Journal of clinical pharmacy and therapeutics.

Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.

G. Sedek, D. Tuerck, F. Pommier, 2007, International journal of clinical pharmacology and therapeutics.

Pharmacokinetic and Pharmacodynamic Evaluation of the Novel CCR1 Antagonist CCX354 in Healthy Human Subjects: Implications for Selection of Clinical Dose

T. Schall, S. Miao, J. Jaén, 2011, Clinical pharmacology and therapeutics.

Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.

Yan-Ling He, S. Schwartz, W. Dole, 2008, International journal of clinical pharmacology and therapeutics.